

1 **Supplementary Materials and Methods**

2 **Animals**

3 Male HAB and NAB mice were selectively inbred for their specific anxiety-related behavior at
4 the Department of Pharmacology, Innsbruck Medical University, Innsbruck (Austria), as
5 described previously ⁴⁷. HABs and NABs (11-22w) had access to food pellets and water *ad*
6 *libitum*, and were group-housed in individually ventilated cages under standard laboratory
7 conditions (12:12 light/dark cycle with lights on at 07:00h, 22 ± 2°C, 45-60% humidity). Sample
8 size was chosen using G-power statistics based on an alpha of 0.05 and a beta of 0.02
9 (statistical power of 80%). The numbers were further validated by the statistics in our
10 previously published studies (Sah et al, 2019) and also of our unpublished observations to
11 estimate that the numbers of animals used in each group were sufficient to arrive to a
12 conclusive result. All experiments were approved by the Austrian Animal Experimentation
13 Ethics Board (Bundesministerium für Wissenschaft Forschung und Wirtschaft, Kommission für
14 Tierversuchsangelegenheiten) and were in compliance with international laws and policies.

15 **Behavioral Testing**

16 All behavioural tests were performed in accordance with established laboratory experimental
17 protocols (44, 69). Behavioral analyses was carried out automatically with VideoMot software
18 tracking (VideoMot 2 Analysis V5.72, TSE) or Ethovision software (12 XT version). The
19 behavioral tests were repeated to replicate the findings.

20

21

22

23 *Elevated Plus Maze*

24 Mice were placed into a plus maze elevated 72cm from the ground, consisting of two closed
25 arms (30 x 5cm) illuminated with red light, and two open arms (30 x 5cm) illuminated with
26 white light at 100 lux, as previously described (37). The test started by placing the mouse on
27 the center platform (5cm x 5cm) facing a closed arm. The behavioural parameters measured
28 included percentage of time spent in the open arms, entries to the open arms, and total
29 distance travelled during the 5min of test duration.

30 *Open Field Test*

31 The open field test consisted of an open box (41 x 41 x 41cm) with a center compartment
32 illuminated at 150lx. Mice were placed in a corner of the open field arena and allowed to
33 explore for 10 min. Parameters measured included total distance travelled, time spent in the
34 center, entries to the center and latency to first entry to center.

35 *Light/Dark Test*

36 The light/dark test was performed in the open field box, but divided into a light arena
37 illuminated at 300lx, and a closed dark chamber at <20lx (black box one third the size of the
38 whole arena) that was accessible through a small door (assigned as transition zone). In brief,
39 mice were placed at the door of the dark chamber and, when it entered the dark chamber, it
40 was allowed to explore the full arena for 10min. Parameters measured included time spent
41 in, number of entries to, distance travelled in, and latency of first entry to the light arena.

42

43

44 **Minocycline Treatment**

45 Minocycline dosages for systemic and local administration were chosen according to previous
46 studies showing effects on microglia and behavior (23, 28). Minocycline (Sigma-Aldrich) was
47 dissolved in tap water and was kept in light-protected drinking bottles for oral administration.
48 Each mouse received an average minocycline dosage of 40mg/kg/day by adjusting the
49 concentrations in the bottles according to the mean bodyweight and daily drinking volume
50 per cage, twice a week for 28d. A randomized block design was used in assigning groups to
51 minocycline/tap water treatment.

52 For local microinjections, minocycline was daily prepared by dissolving in 0.9% sterile saline at
53 a low heat ($20\mu\text{g}/\mu\text{l}$) and infused bilaterally into the DG once daily, for 5d (short-term) or 11d
54 (long-term). A randomized block design was used for assigning groups to minocycline/saline
55 treatment both, in short-term and long-term treatments.

56

57 **Stereotaxic Surgery and Microinjections**

58 HAB mice were placed in a stereotaxic frame (David Kopf Instruments) under 2% isoflurane
59 anesthesia. Guide cannulas (25 gauge, 8mm in length) were implanted 1 mm above the left
60 and right DG (AP:-2.18mm, ML: $\pm 1.40\text{mm}$, DV: -1.2mm from Bregma) and fixed to the skull
61 with two screws and dental cement. The guide cannulas were closed with dummy stylets in
62 order to prevent clogging. Following surgery, mice were single-housed and received
63 buprenorphine (0.5 mg/kg s.c.) and meloxicam (0.5 mg/kg p.o. via drinking water) for
64 analgesic care for up to 3d. Mice were allowed to recover for at least 7d while being
65 habituated to the experimenter and experimental procedure. Minocycline or saline was locally
66 administered once daily for 5d or 11d. Injection cannulas (31 gauge) were connected to

77 Hamilton syringes and, following removal of stylets, inserted into the guide cannulas,
78 extending into the DG by an extra 1mm. Either saline or minocycline solution
79 (0.25 μ l/hemisphere) were infused bilaterally at a speed of 0.1 μ l/min. Microcannula were left
80 in place for an additional 2min. Histological verification of probe placement was performed,
81 and only animals with correct probe placement and no visible brain damage were included in
82 the final analysis.

83 **Immunohistochemistry**

84 At 2h following the light/dark test, all mice were terminally anesthetized with an overdose of
85 thiopental (40mg/kg i.p.). Animals were transcardially perfused with 0.9% saline followed by
86 4% paraformaldehyde in phosphate buffer solution (pH 7.4), as previously described (41).
87 Brains were dissected out and temporarily fixed in 4% paraformaldehyde solution for 2h,
88 followed by permanent storage in phosphate buffer. Coronal sections (40 μ m) were cut using
89 a vibratome (Leica VT 1000S). Fluorescent immunohistochemistry was performed on free-
floating sections, which were incubated overnight at room temperature with the following
primary antibodies, using a standard immunohistochemistry protocol (41): goat anti-Iba1
(1:500 Abcam, #ab107159) and rabbit anti-CD68 (1:300 Abcam, #ab125212) or rabbit anti-
TMEM119 (1:300 Abcam, # ab209064). This was followed by incubation with secondary
donkey anti-goat Alexa Fluor[®] 647 (1:1000 Jackson Immuno Research) and donkey anti-rabbit
Alexa Fluor[®] 568 (1:1000 Invitrogen) antibodies. The sections were then washed in phosphate
buffered saline and mounted onto microscope glass slides (Superfrost Plus, Thermo Scientific),
and cover-slipped with Prolong[™] Gold Antifade Mountant with 4',6-diamidino-2-phenylindole
(DAPI; Invitrogen).

89

90 **Immunofluorescence Microscopy**

91 In one section per mouse, images of both the left and right DG of the hippocampus (Interaural
92 1.98mm, Bregma -1.82mm), representative area consisting of polymorphic, hilus and granular
93 cell layers, were taken using a fluorescent microscope (Olympus, Austria), applying a 4x
94 objective to locate specific brain structures and a 20x objective for quantitative analyses.
95 Additional images were taken of the basolateral amygdala (BLA), nucleus accumbens (NAcc),
96 medial prefrontal cortex (mPFC), cingulate cortex and paraventricular nucleus (PVN) of the
97 hypothalamus. For oral minocycline experiment, both the left and right DG (-1.82mm from
98 Bregma) was assessed. For intra-DG minocycline experiment, Iba-1+ cells were counted at the
99 level of (-2.80mm from Bregma) due to significant tissue tear at the level of -1.82mm that was
100 observed in almost all animals. Quantification of immunopositive-cells was assisted by an
101 image analysis system (cellSens Dimension; Olympus).

102 In addition, Image J software (NIH, USA) was used to objectively quantify Iba1+ cell count
103 (density/mm²), average cell area size (μm²), and % Iba1 coverage of the analyzed area. The
104 threshold was selected and validated by comparing automatic and manual counts. An Iba1-
105 positive cell was considered CD68-positive or TMEM119-positive when Iba1 was spatially co-
106 expressed with a positive CD68 or TMEM119 stain respectively, and were manually quantified
107 in equal representative areas.

108 Experimenters were blinded to animal number codes and thus group allocations, during each
109 behavioral test, microscopic imaging and analysis sessions.

110

111

112 **Statistical Analysis**

113 Data analyses were performed with GraphPad Prism 8.0 software (GraphPad Software Inc.,
114 USA), following the exclusion of outliers identified by Grubb's test. Anderson-Darling and
115 D'Agostino-Pearson tests, GraphPad Prism 8.0 was used to assess normal distribution. For
116 comparison of two groups the unpaired, two-tailed Student's t test (; GraphPad Prism 8.0) was carried
117 out. There were no comparisons of more than two groups, thus ANOVA analysis is not reported in the
118 manuscript. Majority of the data (51x data sets) passed the equal variance test (F test). For 4x data
119 sets, the variance significantly differed and Welch's correction was added to the Student's t test.
120 Correlational analysis was evaluated by Pearson's co-efficiency analysis, Graphpad prism 8.0.
121 Significance was set at $p < 0.05$, and data are presented as means \pm standard error of the mean
122 (S.E.M.).

123

124 **Supplementary Figure and Table Legends**

125

126 **Figure S1. Microglia alterations in select brain regions of HAB vs. NAB mice.**

127 Bars in graphs represent difference between HAB and NAB group means, of Iba1⁺ microglia
128 density, Iba1⁺ microglia cell area average, and percentage of brain region covered by Iba1⁺
129 staining, in various brain regions. Data are presented as HAB mean minus NAB mean. n=7-11,
130 #p=0.10, *p<0.05**p<0.01***p<0.001 (Student's t-test).

131

132 **Figure S2. Microglial alterations in the ventral dentate gyrus (DG) and medial prefrontal**
133 **cortex (PFC) of HAB mice.** Hyperanxious HAB mice show significantly enhanced Iba1⁺ cell
134 density in ventral dentate gyrus (DG), and increased Iba1⁺ cell area average and percentage of

135 coverage by Iba1+ cells of the ventral DG and PFC, compared to NAB controls. Data are
136 presented as mean \pm SEM. n=7-11, *p<0.05**p<0.01 (Student's *t*-test).

137

138 **Figure S3: Representative image of TMEM119⁺ (green) and Iba1⁺ (red) cells in the DG of HAB**
139 **mice.** Iba1 (red) and TMEM119 (green) staining in the dorsal dentate gyrus, outline is DAPI;
140 scale bar 50 μ m. White arrows are Iba1+TMEM119+ cells, black arrows are Iba1+TMEM119-
141 cells.

142

143

144 **Figure S4. Minocycline did not acutely alter anxiety-like behavior in the open field test**
145 **following the first intra-DG microinjection.** On day 1 of 5, no statistically significant
146 differences were found between HAB groups in the open field test (**a**). On day 1 of 11, no
147 statistically significant differences were found between HAB groups in the open field test (**b**).
148 Data are presented as mean \pm SEM. n=7-11, *p<0.05 (Student's *t*-test).

149

150 **Figure S5. Longer period of minocycline induced alterations in the elevated plus maze**
151 **following the last intra-DG microinjection.** On day 11 of 11, intra-DG minocycline HAB group
152 showed increased % of entries to open arm (OA) of the EPM, compared to intra-DG saline HAB
153 group. No statistically significant differences were found between groups for % time spent in
154 OA and total distance travelled. Data are presented as mean \pm SEM. n=7-8, *p<0.05 (Student's
155 *t*-test).